These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Safety and Immunogenicity of an Investigational Respiratory Syncytial Virus Vaccine (RSVPreF3) in Mothers and Their Infants: A Phase 2 Randomized Trial. Bebia Z; Reyes O; Jeanfreau R; Kantele A; De Leon RG; Sánchez MG; Banooni P; Gardener GJ; Rasero JLB; Pardilla MBE; Langley JM; Di Leo CM; Botelho-Nevers E; Buttery J; Laurichesse H; Madhi SA; García AM; Stanley T; Barjat T; Griffith R; Castrejón-Alba MM; de Heusch M; Dieussaert I; Hercor M; Lese P; Qian H; Tullio AN; Henry O J Infect Dis; 2023 Aug; 228(3):299-310. PubMed ID: 36722147 [TBL] [Abstract][Full Text] [Related]
3. A Phase 2 randomized, observer-blind, placebo-controlled, dose-ranging trial of aluminum-adjuvanted respiratory syncytial virus F particle vaccine formulations in healthy women of childbearing age. August A; Glenn GM; Kpamegan E; Hickman SP; Jani D; Lu H; Thomas DN; Wen J; Piedra PA; Fries LF Vaccine; 2017 Jun; 35(30):3749-3759. PubMed ID: 28579233 [TBL] [Abstract][Full Text] [Related]
4. Safety and Immunogenicity of a Respiratory Syncytial Virus Fusion (F) Protein Nanoparticle Vaccine in Healthy Third-Trimester Pregnant Women and Their Infants. Muňoz FM; Swamy GK; Hickman SP; Agrawal S; Piedra PA; Glenn GM; Patel N; August AM; Cho I; Fries L J Infect Dis; 2019 Oct; 220(11):1802-1815. PubMed ID: 31402384 [TBL] [Abstract][Full Text] [Related]
5. Safety and immunogenicity of the PFP vaccine against respiratory syncytial virus (RSV): the western blot assay aids in distinguishing immune responses of the PFP vaccine from RSV infection. Piedra PA; Glezen WP; Kasel JA; Welliver RC; Jewel AM; Rayford Y; Hogerman DA; Hildreth SW; Paradiso PR Vaccine; 1995 Aug; 13(12):1095-101. PubMed ID: 7491817 [TBL] [Abstract][Full Text] [Related]
6. Safety and immunogenicity of a purified F protein respiratory syncytial virus (PFP-2) vaccine in seropositive children with bronchopulmonary dysplasia. Groothuis JR; King SJ; Hogerman DA; Paradiso PR; Simoes EA J Infect Dis; 1998 Feb; 177(2):467-9. PubMed ID: 9466539 [TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of bivalent RSVpreF maternal vaccination to prevent RSV illness in Japanese infants: Subset analysis from the pivotal randomized phase 3 MATISSE trial. Otsuki T; Akada S; Anami A; Kosaka K; Munjal I; Baber J; Shoji Y; Aizawa M; Swanson KA; Gurtman A Vaccine; 2024 Sep; 42(22):126041. PubMed ID: 38853036 [TBL] [Abstract][Full Text] [Related]
8. Respiratory Syncytial Virus Vaccination during Pregnancy and Effects in Infants. Madhi SA; Polack FP; Piedra PA; Munoz FM; Trenholme AA; Simões EAF; Swamy GK; Agrawal S; Ahmed K; August A; Baqui AH; Calvert A; Chen J; Cho I; Cotton MF; Cutland CL; Englund JA; Fix A; Gonik B; Hammitt L; Heath PT; de Jesus JN; Jones CE; Khalil A; Kimberlin DW; Libster R; Llapur CJ; Lucero M; Pérez Marc G; Marshall HS; Masenya MS; Martinón-Torres F; Meece JK; Nolan TM; Osman A; Perrett KP; Plested JS; Richmond PC; Snape MD; Shakib JH; Shinde V; Stoney T; Thomas DN; Tita AT; Varner MW; Vatish M; Vrbicky K; Wen J; Zaman K; Zar HJ; Glenn GM; Fries LF; N Engl J Med; 2020 Jul; 383(5):426-439. PubMed ID: 32726529 [TBL] [Abstract][Full Text] [Related]
9. Purified fusion protein vaccine protects against lower respiratory tract illness during respiratory syncytial virus season in children with cystic fibrosis. Piedra PA; Grace S; Jewell A; Spinelli S; Bunting D; Hogerman DA; Malinoski F; Hiatt PW Pediatr Infect Dis J; 1996 Jan; 15(1):23-31. PubMed ID: 8684872 [TBL] [Abstract][Full Text] [Related]
10. Sequential annual administration of purified fusion protein vaccine against respiratory syncytial virus in children with cystic fibrosis. Piedra PA; Grace S; Jewell A; Spinelli S; Hogerman DA; Malinoski F; Hiatt PW Pediatr Infect Dis J; 1998 Mar; 17(3):217-24. PubMed ID: 9535249 [TBL] [Abstract][Full Text] [Related]
11. Evaluation of the live attenuated cpts 248/404 RSV vaccine in combination with a subunit RSV vaccine (PFP-2) in healthy young and older adults. Gonzalez IM; Karron RA; Eichelberger M; Walsh EE; Delagarza VW; Bennett R; Chanock RM; Murphy BR; Clements-Mann ML; Falsey AR Vaccine; 2000 Mar; 18(17):1763-72. PubMed ID: 10699324 [TBL] [Abstract][Full Text] [Related]
12. Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants. Kampmann B; Madhi SA; Munjal I; Simões EAF; Pahud BA; Llapur C; Baker J; Pérez Marc G; Radley D; Shittu E; Glanternik J; Snaggs H; Baber J; Zachariah P; Barnabas SL; Fausett M; Adam T; Perreras N; Van Houten MA; Kantele A; Huang LM; Bont LJ; Otsuki T; Vargas SL; Gullam J; Tapiero B; Stein RT; Polack FP; Zar HJ; Staerke NB; Duron Padilla M; Richmond PC; Koury K; Schneider K; Kalinina EV; Cooper D; Jansen KU; Anderson AS; Swanson KA; Gruber WC; Gurtman A; N Engl J Med; 2023 Apr; 388(16):1451-1464. PubMed ID: 37018474 [TBL] [Abstract][Full Text] [Related]
13. A Randomized, Controlled, Observer-Blinded Phase 1 Study of the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine With or Without Alum Adjuvant. Langley JM; Aggarwal N; Toma A; Halperin SA; McNeil SA; Fissette L; Dewé W; Leyssen M; Toussaint JF; Dieussaert I J Infect Dis; 2017 Jan; 215(1):24-33. PubMed ID: 27694633 [TBL] [Abstract][Full Text] [Related]
14. Modeling maternal fetal RSV F vaccine induced antibody transfer in guinea pigs. Glenn GM; Fries LF; Smith G; Kpamegan E; Lu H; Guebre-Xabier M; Hickman SP; Flyer D Vaccine; 2015 Nov; 33(47):6488-92. PubMed ID: 26319066 [TBL] [Abstract][Full Text] [Related]
15. RSV Prefusion F Protein-Based Maternal Vaccine - Preterm Birth and Other Outcomes. Dieussaert I; Hyung Kim J; Luik S; Seidl C; Pu W; Stegmann JU; Swamy GK; Webster P; Dormitzer PR N Engl J Med; 2024 Mar; 390(11):1009-1021. PubMed ID: 38477988 [TBL] [Abstract][Full Text] [Related]
16. A Randomized, Blinded, Controlled, Dose-Ranging Study of a Respiratory Syncytial Virus Recombinant Fusion (F) Nanoparticle Vaccine in Healthy Women of Childbearing Age. Glenn GM; Fries LF; Thomas DN; Smith G; Kpamegan E; Lu H; Flyer D; Jani D; Hickman SP; Piedra PA J Infect Dis; 2016 Feb; 213(3):411-22. PubMed ID: 26259809 [TBL] [Abstract][Full Text] [Related]
17. Safety and immunogenicity of an investigational maternal trivalent group B streptococcus vaccine in pregnant women and their infants: Results from a randomized placebo-controlled phase II trial. Swamy GK; Metz TD; Edwards KM; Soper DE; Beigi RH; Campbell JD; Grassano L; Buffi G; Dreisbach A; Margarit I; Karsten A; Henry O; Lattanzi M; Bebia Z Vaccine; 2020 Oct; 38(44):6930-6940. PubMed ID: 32883555 [TBL] [Abstract][Full Text] [Related]
18. A phase 1a, first-in-human, randomized study of a respiratory syncytial virus F protein vaccine with and without a toll-like receptor-4 agonist and stable emulsion adjuvant. Falloon J; Ji F; Curtis C; Bart S; Sheldon E; Krieger D; Dubovsky F; Lambert S; Takas T; Villafana T; Esser MT Vaccine; 2016 May; 34(25):2847-54. PubMed ID: 27102821 [TBL] [Abstract][Full Text] [Related]
19. Serum, breast milk, and infant antibody after maternal immunisation with pneumococcal vaccine. Shahid NS; Steinhoff MC; Hoque SS; Begum T; Thompson C; Siber GR Lancet; 1995 Nov; 346(8985):1252-7. PubMed ID: 7475716 [TBL] [Abstract][Full Text] [Related]
20. Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in ambulatory adults over age 60. Falsey AR; Walsh EE Vaccine; 1996 Sep; 14(13):1214-8. PubMed ID: 8961507 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]